Alizé Pharma company
Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.
Total Funding:
€81.2M
Headquarters:
Écully, Rhone-Alpes, France
Funding Status:
M&A
Employee Number:
1-10
Estimated Revenue:
Less than $1M
Last Funding Type:
Series A
Technology:
P4 Medicine
Investors Number:
12
Founded Date:
2008-01-01
Industry:
Biotechnology, Health Care, Science and Engineering